CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells


Arisan E. D. , Obakan P. O. , ÇOKER GÜRKAN A., Calcabrini A., Agostinelli E., Unsal N. P.

CURRENT PHARMACEUTICAL DESIGN, vol.20, no.2, pp.180-188, 2014 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 2
  • Publication Date: 2014
  • Doi Number: 10.2174/13816128113199990029
  • Journal Name: CURRENT PHARMACEUTICAL DESIGN
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.180-188
  • Keywords: Polyamines, CDK inhibitors, purvalanol, roscovitine, prostate cancer, CYCLIN-DEPENDENT KINASE, SPERMINE OXIDASE, ORNITHINE-DECARBOXYLASE, ANDROGEN RECEPTOR, EPITHELIAL-CELLS, DOWN-REGULATION, LEUKEMIA-CELLS, R-ROSCOVITINE, AMINE OXIDASE, PURVALANOL-A

Abstract

Androgen signaling is critical in prostate cancer development and progression. The co-existence of hormone responsive and irresponsive cells due to functional androgen receptor (AR) in prostate gland is the major obstacle in prostate cancer therapy models. Targeting aberrant cell cycle by novel cell cycle blocking agents is a promising strategy to treat various types of malignancies. Purvalanol and roscovitine are cyclin dependent kinase (CDK) inhibitors able to activate apoptotic cell death by inducing cell cycle arrest at G1/S and G2/M phases in cancer cells. Polyamines are unique cationic amine derivatives involved in the regulation of cell proliferation. Although the elevated intracellular level of polyamines (putrescine, spermidine and spermine) is typical for prostate gland, abnormal regulation of polyamine metabolism might result in rapid cell proliferation and, thus in prostate cancer progression. Therefore, treatment with drug-induced depletion of intracellular polyamine levels through the activated polyamine catabolism is critical to achieve successful strategies for prostate cancer.